Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Scemblix (asciminib) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors (TKIs), and for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with the T315I mutation.
• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Major Molecular Response (MMR) Rate at 6 Months: Asciminib (Scemblix) shows an MMR rate of 23.3-25.5%, which is higher than omacetaxine (19.2%) and bosutinib (13.2%) but within the range of Ponatinib (19.0-66.7%).
• Complete Cytogenetic Response (CCyR) Rate at 6 Months: Asciminib (Scemblix) demonstrates a CCyR rate of 38.7-40.8%, higher than omacetaxine (16.1%) and bosutinib (18-24.2%) and within Ponatinib's variable range of 21.4-64.8%.
• Population Focus: The data pertains to adult patients with chronic phase-chronic myeloid leukemia (CP-CML) who had received ≥2 prior tyrosine kinase inhibitors (TKIs).
• There is no safety information available in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.